Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513383 · ClinicalTrials.gov registry record · Phase 1
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00513383: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00513383 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00513383, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer. Another goal of this study is to find the highest dose of the study drugs that can be given safely without causing serious sife effects. Panitumumab is a type of drug called a monoclonal antibody that has been studied in other types of cancers, such as kidney and colon. This monoclonal antibody is directed against the epidermal growth factor receptor (EGFR). EGFR has been found on the majority of head and neck cancer cells. By blocking EGFR, this monoclonal antibody may inhibit the growth of head and neck cancer cells.
Interventions
- DRUG Panitumumab
- DRUG Carboplatin
- DRUG Paclitaxel
- RADIATION Intensity Modulated Radiation Therapy
- DRUG 5-Fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-04 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513383
The ClinicalTrials.gov registry entry for NCT00513383 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Panitumumab is the first listed.
NCT00513383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513383 about?
NCT00513383 is a clinical study titled "Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck". This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer. Another goal of this study is to find the highest dose of the study drugs that can be given safely without causing serious sife effects. Panitumumab is a ...
What is the current status of trial NCT00513383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2006-04. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00513383?
The interventions under investigation include: Panitumumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), Intensity Modulated Radiation Therapy (RADIATION), 5-Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT00513383?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.